Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Revenues for BIOCON are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.13600
forwardPE 27.83316
debtToEquity 66.25900
earningsGrowth 1.54700
revenueGrowth 0.12800
grossMargins 0.65944
operatingMargins 0.14532
trailingEps 8.44000
forwardEps 9.92000

Biocon Limited's current ratio of 1.136 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring Biocon Limited is unlikely to face difficulties in meeting immediate financial obligations.
BIOCON's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
BIOCON's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that BIOCON will continue to grow its operations, driven by increasing profits and revenue.
BIOCON's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that BIOCON's financial performance will improve in the current financial year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

The stock price of BIOCON has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Insider Transactions:

Insider Transactions for BIOCON
Insider Transactions for BIOCON


BIOCON stock was sold in 1 transactions, with market price at 264.1499938964844.There were no sell transactions throughout the period under consideration.More recent purchases than sales at current price levels for BIOCON could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts are favoring BIOCON with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider BIOCON as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.